Gloved hand holding a petri dish with bacterial colonies growing on the surface, used for scientific research.

Functional Abdominal Pain (FAP)

Functional abdominal pain (FAP) affects up to a fifth of all school-aged children and is among the most commonly diagnosed medical problems in the field of paediatrics. However, the causes behind the condition are still unclear.

<

Functional Abdominal Pain (FAP)

Two trials with Limosilactobacillus reuteri Protectis® (BioGaia®) have shown it to have a positive effect on those suffering from FAP.

Of course, not all strains of probiotics are equal; different strains have different properties and effects. Limosilactobacillus reuteri Protectis® is a powerful strain that colonizes the entire gastrointestinal (GI) tract.

BioGaia® Protectis® supports the GI tract

  • Supports gastric emptying and improves GI motility
  • Can help to reduce the frequency and severity of pain
  • May improve gastric mucosal integrity
  • Promote overall digestive health in children and adults
  • Healthy bacterial balance in the digestive tract in balance contribute to gut comfort and overall wellbeing.

BioGaia® Probiotic Tablets

Limosilactobacillus reuteri Protectis® has been shown to promote healthy digestive health and function.

BioGaia® Dosage recommendations

One chewable tablet or 5 drops a day.

Double blind study

Limosilactobacillus reuteri Protectis® (DSM 17938) vs placebo in children with functional abdominal pain.

Weizman Z., Blumin V. Abu-Abed J., Binsztok M.: J Pediatr. 2016:174:160-164.

Bar chart comparing different data points with yellow and gray bars, each labeled with specific values

Results

  • Significant relief in frequency (p<0.02) and severity (p<0.01) of abdominal pain compared to placebo at 4 weeks.
  • Continuously and significantly relieved severity of abdominal pain compared to placebo at 8 weeks.
  • Reduced incidence of perceived abdominal distension and bloating compared to placebo at 4 weeks (p=0.013).

Conclusions

  • Demostrates that L. reuteri Protectis® was effective in treating functional abdominal pain in children.
  • L. reuteri Protectis® significantly reduced the frequency and severity of functional abdominal pain in children

Facts

  • Double blind, placebo-controlled study
  • 93 children aged 6-15 years with functional abdominal pain (Rome III criteria)
  • One chewable tablet Limosilactobacillus reuteri Protectis® (BioGaia®) 108 CFU/day daily (n=47) or placebo (n=46) for 4 weeks with follow-up of additional 4 weeks

RCT study

Limosilactobacillus reuteri Protectis® (DSM 17938) in the treatment of functional abdominal pain in children.

Jadrešin O, Hojsak I, Mišak Z, Kekez AJ, Trbojević T, Ivković L, Kolaček S.
J Pediatr Gastroenterol Nutr. online 30 Nov 2016. doi: 10.1097/MPG.0000000000001478

Bar chart comparing two data points with a gray bar labeled 46% and a yellow bar labeled 80%, connected by a dotted line.
Bar chart comparing multiple data points with yellow and gray bars, each labeled with specific values and connected by dotted lines

Results

  • Significantly more pain-free days compared to placebo: 80% vs. 46% (p<0.05)
  • Both groups showed significant reduction in severity of pain compared to baseline
  • Retained effect on severity of pain. by L. reuteri Protectis® during the follow-up month
  • First study to suggest that L. reuteri Protectis® may be effective in children with IBS

Conclusions

  • Demonstrates that L. reuteri Protectis® was effective in treating functional abdominal pain in childran
  • L. reuteri Protectis® significantly reduced the number of days with pain and had a retained effect on severity of pain after supplementation of the study product had ended.

Facts

  • Double blind, placebo-controlled study
  • 55 children aged 4-18 years with functional abdominal pain or irritable bowel syndrome (Rome III criteria)
  • One chewable tablet Limosilactobacillus reuteri Protectis® (BioGaia®) 108 CFU/day daily (n=26) or placebo (n=29) for 12 weeks of intervention with follow-up of additional 4 weeks